Hints and tips:
Related Special Reports
...The New York-based pharma group has acquired four companies — Arena, ReViral, Biohaven and Global Blood Therapeutics — that it expects will contribute about $10bn in revenues in 2030....
...The Medicines and Healthcare products Regulatory Agency has approved the therapy, called Casgevy, which was developed by Vertex Pharmaceuticals and Crispr Therapeutics....
...It acquired obesity drug developer Carmot Therapeutics for $2.7bn....
...molnupiravir or Paxlovid will [still] be effective, now that most people have been either vaccinated or infected,” said Andy Hill, a senior visiting research fellow at Liverpool university’s pharmacology and therapeutics...
...to rescue Farfetch Regulators even out the antitrust score Global regulators had been on a losing streak lately, with back-to-back losses including Amgen’s $28bn takeover of fellow drugmaker Horizon Therapeutics...
...Monday’s acquisition by Novartis of Seattle-based biotech firm Chinook Therapeutics for up to $3.5bn is a case in point....
...Pfizer spent $6.7bn on Arena Pharmaceuticals in December, lured by its medicines for immune-inflammatory diseases, and paid $2.3bn in August last year for Trillium Therapeutics as it targeted treatments...
...The Regeneron chief executive has backed an attempt by US regulators to block Amgen’s $28bn acquisition of Horizon Therapeutics as he accused some pharmaceutical companies of abusing their market power to...
...Andrew Hill, a senior visiting research fellow at Liverpool university’s pharmacology and therapeutics department, said the drug also had potential side effects for pregnant women....
...Massachusetts-based Luminopia, which creates therapeutic visual stimuli, raised $16mn in late June....
...regulators have warned that “rampant consolidation” in the pharmaceuticals industry is pushing up prices for patients as the Federal Trade Commission sued to block Amgen’s $28.3bn deal to acquire Horizon Therapeutics...
...Amgen has reached an agreement with the US antitrust regulator that allows the drugmaker to press ahead with its $28bn acquisition of Horizon Therapeutics....
...Khan has become such an antagonist for dealmakers and why they were rejoicing this month when Amgen reached a settlement with her agency, allowing the pharmaceutical company’s $28bn acquisition of Horizon Therapeutics...
...The Federal Trade Commission sued to block the biotechnology company Amgen’s $28.3bn deal to acquire Horizon Therapeutics, Italy is struggling to spend €200bn in EU Covid recovery funds, and Ukraine said...
...His comments came after the US Federal Trade Commission on Tuesday sued to block Amgen’s $28bn takeover of Horizon Therapeutics....
...In December, biopharmaceutical firm Amgen announced the acquisition of biotech star Horizon Therapeutics for $116.50 per share or $28bn in aggregate....
...Amgen is close to a deal to acquire Horizon Therapeutics in a transaction worth as much as $20bn, according to sources familiar with the matter, as a sell-off in healthcare stocks creates attractive targets...
...Amgen has agreed to buy Horizon Therapeutics for $28.3bn, including debt, after the California-based biotech won a three-way race to secure a new pipeline of drugs for rare autoimmune and inflammatory diseases...
...Late last year, Amgen bought Horizon Therapeutics for $28bn. Biotech and life science valuations have moderated since 2021. But the chance for premium buyouts has not disappeared....
...The FTC attempted to block Amgen’s $28.3bn takeover of Horizon Therapeutics. Barriers to M&A are going to make it harder for pharma companies to replenish drug pipelines....
...US Department of Justice, intend to follow through on their mission to draw a tougher line on antitrust.Still outstanding are large contested deals, including Amgen’s planned $28bn takeover of Horizon Therapeutics...
...Astellas, Japan’s second-largest pharmaceutical company by revenue, has spent more than ¥1tn ($7.3bn) in overseas acquisitions and partnerships since 2007, including its $3bn purchase of US drugmaker Audentes Therapeutics...
...As the EU approved Microsoft’s $75bn bid to buy Activision Blizzard, the US Federal Trade Commission sued to block Amgen’s $28.3bn deal to acquire Horizon Therapeutics and warned of “rampant consolidation...
...The deal follows Amgen’s $28.3bn acquisition of the Californian biotech Horizon Therapeutics in December. In 2023, Seagen expects revenue of about $2.2bn, a 12 per cent rise year on year....
...It’s litigating an order for Illumina to divest cancer screening company Grail in a vertical merger case and has also sued to block Amgen’s $28bn takeover of Horizon Therapeutics....
International Edition